ORBIMED ADVISORS LLC
13F Reported Value
ⓘ$5.0B
incl. option notional
Equity Holdings
ⓘ$4.6B
Option Notional
ⓘ$459.9M
$0 puts / $459.9M calls
Holdings
112
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
ORBIMED ADVISORS LLC disclosed 112 positions worth $5.0B in its Form 13F-HR for Q1 2026 — $4.6B in common stock plus $459.9M of put/call option positions (reported at underlying notional value, not premium at risk), led by $EWTX (Edgewise Therapeutics, Inc.) at 10.7% of the equity portfolio, followed by $ELVN and $MDXH. During the quarter the fund opened 28 new positions and exited 23 — including a new stake in $MDXH and a full exit from $TERN. The portfolio is most concentrated in Healthcare (97.6% of disclosed assets). All figures are sourced directly from ORBIMED ADVISORS LLC’s Form 13F-HR filing with the SEC under CIK 1055951.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$488.8M15,518,492 sh - —
Quality
$312.0M7,959,538 sh - —
Quality
$285.9M124,306,000 sh - 89.3
Quality
$217.8M236,800 sh - —
Quality
$184.5M2,718,735 sh - 29.6
Quality
$154.4M40,966,100 sh - 79.9
Quality
$149.5M2,382,100 sh - —
Quality
$141.5M3,530,702 sh - —
Quality
$132.2M670,200 sh - 30.2
Quality
$122.9M125,000,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Edgewise Therapeutics, Inc.$EWTX | — | $488.8M | 15,518,492 |
 Enliven Therapeutics, Inc.$ELVN | — | $312.0M | 7,959,538 |
 MDxHealth SA$MDXHCALL | — | $285.9M | 124,306,000 |
 ELI LILLY & Co$LLY | 89.3 | $217.8M | 236,800 |
 SINOVAC BIOTECH LTD$SVA | — | $184.5M | 2,718,735 |
 AVITA Medical, Inc.$RCELCALL | 29.6 | $154.4M | 40,966,100 |
 BOSTON SCIENTIFIC CORP$BSX | 79.9 | $149.5M | 2,382,100 |
 Sionna Therapeutics, Inc.$SION | — | $141.5M | 3,530,702 |
 ASTRAZENECA PLC$AZN | — | $132.2M | 670,200 |
 MYRIAD GENETICS INC$MYGN | 30.2 | $122.9M | 125,000,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ORBIMED ADVISORS LLC's 112 positions.
Showing top 10 of 112 holdings.
Sector Allocation
Healthcare
$4.5B
Technology
$87.0M
Energy
$22.1M
Full Holdings — ORBIMED ADVISORS LLC (Q1 2026)
All 112 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $EWTX | Edgewise Therapeutics, Inc. | $488.8M | 10.7% | +0% | — |
| 2 | $ELVN | Enliven Therapeutics, Inc. | $312.0M | 6.8% | +0% | — |
| 3 | $MDXHCALL | MDxHealth SA | $285.9M | — | NEW | — |
| 4 | $LLY | ELI LILLY & Co | $217.8M | 4.8% | -21% | 89.3 |
| 5 | $SVA | SINOVAC BIOTECH LTD | $184.5M | 4.0% | +0% | — |
| 6 | $RCELCALL | AVITA Medical, Inc. | $154.4M | — | NEW | 29.6 |
| 7 | $BSX | BOSTON SCIENTIFIC CORP | $149.5M | 3.3% | -2% | 79.9 |
| 8 | $SION | Sionna Therapeutics, Inc. | $141.5M | 3.1% | -1% | — |
| 9 | $AZN | ASTRAZENECA PLC | $132.2M | 2.9% | NEW | — |
| 10 | $MYGN | MYRIAD GENETICS INC | $122.9M | 2.7% | NEW | 30.2 |
| 11 |  $MBX | MBX Biosciences, Inc. | $108.6M | 2.4% | -8% | — |
| 12 |  $CRVS | Corvus Pharmaceuticals, Inc. | $104.8M | 2.3% | +0% | — |
| 13 |  $ARGX | ARGENX SE | $100.0M | 2.2% | -6% | — |
| 14 |  $EW | Edwards Lifesciences Corp | $98.5M | 2.1% | -33% | 67.6 |
| 15 |  $ISRG | INTUITIVE SURGICAL INC | $96.2M | 2.1% | -21% | 81.4 |
| 16 |  $CMPX | Compass Therapeutics, Inc. | $80.5M | 1.8% | +0% | — |
| 17 |  $MRK | Merck & Co., Inc. | $79.8M | 1.7% | NEW | 70.9 |
| 18 |  $GPCR | Structure Therapeutics Inc. | $71.1M | 1.6% | +27% | — |
| 19 |  $AVBP | ArriVent BioPharma, Inc. | $69.8M | 1.5% | +0% | — |
| 20 |  $IRON | Disc Medicine, Inc. | $68.3M | 1.5% | +0% | — |
| 21 |  $SPRY | ARS Pharmaceuticals, Inc. | $66.6M | 1.4% | +0% | 29.7 |
| 22 |  $CGON | CG Oncology, Inc. | $64.2M | 1.4% | -37% | 28 |
| 23 |  $XENE | Xenon Pharmaceuticals Inc. | $61.6M | 1.3% | +137% | 12.9 |
| 24 |  $SYK | STRYKER CORP | $60.0M | 1.3% | -44% | 69.8 |
| 25 |  $BMY | BRISTOL MYERS SQUIBB CO | $56.1M | 1.2% | +19% | 70.1 |
| 26 |  $MLYS | Mineralys Therapeutics, Inc. | $55.6M | 1.2% | +109% | — |
| 27 |  $PRAX | Praxis Precision Medicines, Inc. | $55.6M | 1.2% | +83% | — |
| 28 |  $PFE | PFIZER INC | $54.7M | 1.2% | +18% | 69 |
| 29 |  $DYN | Dyne Therapeutics, Inc. | $52.9M | 1.1% | +32% | — |
| 30 |  $NTRA | Natera, Inc. | $52.4M | 1.1% | -28% | 46.4 |
| 31 |  $ABVX | Abivax S.A. | $51.9M | 1.1% | +27% | — |
| 32 |  $UPB | Upstream Bio, Inc. | $51.2M | 1.1% | +0% | 22.6 |
| 33 |  $DHR | DANAHER CORP /DE/ | $50.4M | 1.1% | -11% | 63.9 |
| 34 |  $CAI | Caris Life Sciences, Inc. | $50.2M | 1.1% | -10% | 32 |
| 35 | $RCEL | AVITA Medical, Inc. | $42.5M | 0.9% | NEW | 29.6 |
| 36 |  $ASND | Ascendis Pharma A/S | $41.6M | 0.9% | +6% | 41.5 |
| 37 |  $STTK | Shattuck Labs, Inc. | $40.5M | 0.9% | +0% | — |
| 38 |  $GH | Guardant Health, Inc. | $40.2M | 0.9% | NEW | 36.1 |
| 39 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $39.4M | 0.9% | -59% | 60.9 |
| 40 |  $PRLD | Prelude Therapeutics Inc | $37.3M | 0.8% | +0% | 27 |
| 41 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $36.3M | 0.8% | +0% | 26.5 |
| 42 |  $AXSM | Axsome Therapeutics, Inc. | $36.2M | 0.8% | -15% | 36.6 |
| 43 |  $QURE | uniQure N.V. | $34.9M | 0.8% | +190% | — |
| 44 |  $ORIC | Oric Pharmaceuticals, Inc. | $34.1M | 0.7% | -26% | — |
| 45 |  $ELV | Elevance Health, Inc. | $33.6M | 0.7% | +16% | 59.4 |
| 46 |  $RLMD | RELMADA THERAPEUTICS, INC. | $32.8M | 0.7% | +81% | — |
| 47 |  $FBRX | Forte Biosciences, Inc. | $31.0M | 0.7% | +0% | — |
| 48 |  $TRVI | Trevi Therapeutics, Inc. | $29.3M | 0.6% | -23% | — |
| 49 |  $ESPR | Esperion Therapeutics, Inc. | $29.0M | 0.6% | +77% | 34.3 |
| 50 |  $NPCE | NeuroPace Inc | $27.6M | 0.6% | -13% | 30.5 |
| 51 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $27.3M | 0.6% | +31% | 30.3 |
| 52 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $22.9M | 0.5% | +0% | 63.7 |
| 53 |  $SNDX | Syndax Pharmaceuticals Inc | $22.5M | 0.5% | NEW | 30 |
| 54 |  $NOV | NOV Inc. | $22.1M | 0.5% | +0% | 50.1 |
| 55 |  $BTSG | BrightSpring Health Services, Inc. | $21.2M | 0.5% | +2% | 64.3 |
| 56 |  $LXEO | Lexeo Therapeutics, Inc. | $20.7M | 0.5% | +70% | — |
| 57 |  $STRO | SUTRO BIOPHARMA, INC. | $20.0M | 0.4% | NEW | 30.1 |
| 58 |  $NKTR | NEKTAR THERAPEUTICS | $19.8M | 0.4% | NEW | 10.2 |
| 59 |  $HELP | CYBIN INC. | $18.4M | 0.4% | -0% | — |
| 60 |  $KRYS | Krystal Biotech, Inc. | $17.8M | 0.4% | -42% | 75.9 |
| 61 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $16.8M | 0.4% | NEW | — |
| 62 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $16.3M | 0.4% | +9% | — |
| 63 |  $URGN | UroGen Pharma Ltd. | $15.7M | 0.3% | +0% | — |
| 64 |  $DFTX | Definium Therapeutics, Inc. | $15.2M | 0.3% | NEW | — |
| 65 |  $VERA | Vera Therapeutics, Inc. | $14.9M | 0.3% | +5% | — |
| 66 |  $QTTB | Q32 Bio Inc. | $14.5M | 0.3% | +0% | 23.1 |
| 67 |  $WHWK | Whitehawk Therapeutics, Inc. | $14.4M | 0.3% | +0% | 9.6 |
| 68 |  $AMGN | AMGEN INC | $14.0M | 0.3% | NEW | 79.5 |
| 69 |  $ALHC | Alignment Healthcare, Inc. | $13.9M | 0.3% | NEW | 63 |
| 70 |  $EYPT | EyePoint, Inc. | $13.8M | 0.3% | -57% | 10.3 |
| 71 |  $JANX | Janux Therapeutics, Inc. | $13.7M | 0.3% | -50% | 24.8 |
| 72 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $13.6M | 0.3% | -18% | 37.2 |
| 73 |  $BCAX | Bicara Therapeutics Inc. | $13.3M | 0.3% | +219% | — |
| 74 |  $BIOA | BioAge Labs, Inc. | $12.4M | 0.3% | -10% | 28.6 |
| 75 |  $COGT | Cogent Biosciences, Inc. | $12.4M | 0.3% | -13% | — |
| 76 |  $ALMS | ALUMIS INC. | $12.1M | 0.3% | -50% | 9.2 |
| 77 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $11.4M | 0.3% | NEW | 75.1 |
| 78 |  $CARL | CARLSMED, INC. | $11.3M | 0.3% | +0% | 45.1 |
| 79 |  $BIIB | BIOGEN INC. | $11.3M | 0.3% | NEW | 65.6 |
| 80 |  $QGENCALL | QIAGEN N.V. | $10.0M | — | NEW | — |
| 81 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $8.7M | 0.2% | -4% | — |
| 82 |  $KROS | Keros Therapeutics, Inc. | $8.4M | 0.2% | -6% | 57.2 |
| 83 |  $GILD | GILEAD SCIENCES, INC. | $8.3M | 0.2% | NEW | 77.8 |
| 84 |  $HRTX | HERON THERAPEUTICS, INC. /DE/ | $7.9M | 0.2% | NEW | 30.6 |
| 85 |  $AVTX | Avalo Therapeutics, Inc. | $7.1M | 0.1% | -60% | 4.6 |
| 86 |  $TECX | Tectonic Therapeutic, Inc. | $7.0M | 0.1% | -61% | — |
| 87 |  $ACET | Adicet Bio, Inc. | $7.0M | 0.1% | +0% | — |
| 88 |  $CMPS | COMPASS Pathways plc | $6.4M | 0.1% | NEW | — |
| 89 | $PVLACALL | PALVELLA THERAPEUTICS, INC. | $6.2M | — | NEW | — |
| 90 |  $PHVS | Pharvaris N.V. | $5.8M | 0.1% | +0% | — |
| 91 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $5.7M | 0.1% | NEW | — |
| 92 |  $AORT | ARTIVION, INC. | $5.5M | 0.1% | NEW | 48.8 |
| 93 |  $NSPR | InspireMD, Inc. | $5.1M | 0.1% | +0% | — |
| 94 |  $RVMD | Revolution Medicines, Inc. | $5.1M | 0.1% | +101% | — |
| 95 |  $ADCT | ADC Therapeutics SA | $4.9M | 0.1% | -77% | 16.3 |
| 96 |  $PTGX | Protagonist Therapeutics, Inc | $4.4M | 0.1% | +94% | 24.8 |
| 97 |  $PALI | PALISADE BIO, INC. | $4.1M | 0.1% | +25% | — |
| 98 |  $ANRO | Alto Neuroscience, Inc. | $3.8M | 0.1% | +34% | — |
| 99 |  $SVRA | Savara Inc | $3.5M | 0.1% | NEW | — |
| 100 |  $CGEM | Cullinan Therapeutics, Inc. | $3.5M | 0.1% | -10% | — |
| 101 |  $SLNOCALL | SOLENO THERAPEUTICS INC | $3.3M | — | NEW | 46.3 |
| 102 |  $PTCT | PTC THERAPEUTICS, INC. | $3.3M | 0.1% | +112% | 80 |
| 103 |  $LFST | LifeStance Health Group, Inc. | $3.2M | 0.1% | NEW | 53.7 |
| 104 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $2.9M | 0.1% | NEW | — |
| 105 |  $JBIO | Jade Biosciences, Inc. | $2.6M | 0.1% | -65% | — |
| 106 |  $CCCC | C4 Therapeutics, Inc. | $2.3M | 0.1% | -39% | 6.5 |
| 107 |  $KALV | KalVista Pharmaceuticals, Inc. | $1.9M | 0.0% | -75% | 25.9 |
| 108 |  $IMA | ImageneBio, Inc. | $1.9M | 0.0% | +0% | 3.9 |
| 109 |  $VTGN | Vistagen Therapeutics, Inc. | $1.7M | 0.0% | +0% | — |
| 110 |  $ATAI | Atai Beckley N.V. | $1.2M | 0.0% | NEW | — |
| 111 | $COGT | Cogent Biosciences, Inc. | $1.2M | 0.0% | +0% | — |
| 112 |  $TRAW | Traws Pharma, Inc. | $1.1M | 0.0% | +0% | — |
New Positions (28)
$MDXHCALL MDxHealth SA$285.9M$RCELCALL AVITA Medical, Inc.$154.4M$AZN ASTRAZENECA PLC$132.2M$MYGN MYRIAD GENETICS INC$122.9M$MRK Merck & Co., Inc.$79.8M$RCEL AVITA Medical, Inc.$42.5M$GH Guardant Health, Inc.$40.2M$SNDX Syndax Pharmaceuticals Inc$22.5M$STRO SUTRO BIOPHARMA, INC.$20.0M$NKTR NEKTAR THERAPEUTICS$19.8M$PVLA PALVELLA THERAPEUTICS, INC.$16.8M$DFTX Definium Therapeutics, Inc.$15.2M$AMGN AMGEN INC$14.0M$ALHC Alignment Healthcare, Inc.$13.9M$REGN REGENERON PHARMACEUTICALS, INC.$11.4MExited Positions (23)
$TERN Terns Pharmaceuticals, Inc.
$APLS Apellis Pharmaceuticals, Inc.
$CI Cigna Group
$RAPT RAPT Therapeutics, Inc.
$UTHR UNITED THERAPEUTICS Corp
$ROIV Roivant Sciences Ltd.
$RNA Avidity Biosciences, Inc.
$NBIX NEUROCRINE BIOSCIENCES INC
$EXK ENDEAVOUR SILVER CORP
$BRKR BRUKER CORP
$CTMX CytomX Therapeutics, Inc.
$VIR Vir Biotechnology, Inc.$EWCALL Edwards Lifesciences Corp
$TARS Tarsus Pharmaceuticals, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ORBIMED ADVISORS LLC including:
Track ORBIMED ADVISORS LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ORBIMED ADVISORS LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ORBIMED ADVISORS LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ORBIMED ADVISORS LLC (SEC CIK: 1055951), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ORBIMED ADVISORS LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.